The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
Abstract
The inclusion of HIV protease inhibitor (PI) drugs in so-called `highly active antiretroviral therapy' (HAART) has substantially improved the clinical perspectives for HIV-infected individuals, but full eradication of HIV infection is still an unachieved goal [1,2] One of the factors that may limit the therapeutic efficacy of PIs is the activity of P-glycoprotein (P-gp). This plasma membrane localized drug transporter can actively extrude the currently used PIs from cells. P-gp is not only present in a subfraction of lymphocytes, one of the main targets of HIV, but also in a range of pharmacological barriers that could give rise to potential HIV sanctuary sites in the body, such as brain and testis. Moreover, PI oral bioavailability and penetration into the foetus also appears to be hindered by P-gp activity. P-gp may therefore limit the penetration of the PI into several therapeutically relevant compartments, and thus diminish the chance of achieving a curative treatment regimen. This review focuses on current insights into the pharmacological role of P-gp for PI disposition, and on potential strategies to interfere with P-gp function that could lead to an improvement of current HIV pharmacotherapy. Multidrug resistance and drug transport mediated by P-glycoprotein P-glycoprotein and multidrug resistance P-gp was originally discovered due to its ability to cause multidrug resistance (MDR) in tumour cells [3,4] This large, glycosylated plasma membrane protein is capable of pumping a wide range of relatively hydrophobic, amphipathic drugs out of cells. P-gp belongs to the ATP-binding cassette family of proteins [5] and ATP hydrolysis provides the energy for active drug extrusion, which can occur against steep concentration gradients. P-gp activity decreases the concentration of transported drugs at intracellular target sites, and thus confers resistance to, for example, the cytotoxic activity of many anticancer drugs. Transported substrates of P-gp are structurally very diverse, they can range in size from about 200 to 1800 Da, and they include, in addition to many anticancer agents, a large number of other currently used drugs. The PIs indinavir, saquinavir, nelfinavir and ritonavir are amongst these, as all have been shown to be actively transported by P-gp [6–9] The previously demonstrated profound impact of P-gp on the pharmacological behaviour of several anticancer and other drugs may therefore well extend to the PIs. P-glycoprotein blockers From the perspective that P-gp can contribute to MDR in clinical tumours, there has been great interest in the development of compounds that block P-gp activity [10,11] Co-administration of such blockers with conventional chemotherapy to cancer patients might reverse the P-gp-mediated MDR of the tumour, and thus enhance the response to chemotherapy. The feasibility of this strategy in patients is currently being investigated (see e.g., [12], and several P-gp blockers with high efficacy and acceptable or even very low toxicity have been developed. Examples of such compounds are the Cyclosporin A analogue PSC833 [13] the acridonecarboxamide derivative GF120918 (or GG918) [14] and the cyclopropyldibenzosuberane LY335979 [15] P-gp blockers are as structurally diverse as the known P-gp substrates, and many blockers are themselves transported to some extent by P-gp, suggesting that they act by inhibiting competitively (e.g., [16]. P-glycoprotein knockout mice One concern with the clinical application of P-gp blockers was that interference with the normal physiological function of the drug-transporting P-gp might not be compatible with normal life. To address this concern, knockout mice were developed in our institute that are fully deficient for the drug-transporting P-gps [17,18] Unlike humans, who have only one drug-transporting P-gp, MDR1, mice have two, Mdr1a and Mdr1b, but substrate specificity and tissue distribution of these three proteins overlap strongly, making it very likely that the two mouse proteins together perform the same functions as the single human protein. Analysis of the Mdr1-type P-gp knockout mice showed that drug-transporting P-gps are not essential for viability, fertility and a normal life span, suggesting that a full blockade of P-gp activity in humans using pharmacological blockers may be acceptable. Moreover, the mice allowed us to demonstrate the prominent role that P-gp has in the pharmacological behaviour of a range of drugs and toxins. By comparing the pharmacological behaviour of drugs in wild-type mice treated with effective P-gp blockers and in Mdr1-type knockout mice, we could further demonstrate that several pharmacological functions of Mdr1-type P-gp can be inhibited completely with such P-gp blockers. Tissue distribution of P-glycoprotein and its pharmacological roles Blood–brain barrier and blood–testis barrier P-gp is abundant in the luminal face of endothelial cells in blood capillaries of the brain and some peripheral nerves an
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., et al. (1997) · Science · doi:10.1126/science.278.5341.1295 · Cited by 3,098
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
Wong, J. K., Hezareh, M., Günthard, H. F., Havlir, D. V., Ignacio, C. C., Spina, C. A., & Richman, D. D. (1997) · Science · doi:10.1126/science.278.5341.1291 · Cited by 2,186
Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., et al. (1999) · Nature Medicine · doi:10.1038/8394 · Cited by 2,119
Cited by
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00169-2 · Cited by 1,386
Self-citationMammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.027 · Cited by 1,231
Self-citationFellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J.-P., Decosterd, L. A., Furrer, H., Opravil, M., Pantaleo, G., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07276-8 · Cited by 658
Self-citationImpact of Drug Transporter Studies on Drug Discovery and Development
Mizuno, N., Niwa, T., Yotsumoto, Y., & Sugiyama, Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.1 · Cited by 490
Genetic Polymorphisms of the Human MDR1 Drug Transporter
Schwab, M., Eichelbaum, M., & Fromm, M. F. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140233 · Cited by 308
Metadata
- Authors
- Huisman, M. T., Smit, J. W., & Schinkel, A. H.
- Venue
- AIDS
- Published
- 2000-02
- Volume
- 14
- Issue
- 3
- Pages
- 237-242
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2329313939
- Cited by
- 177
- References
- 3
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. https://app.cochat.ai/papers/10.1097/00002030-200002180-00005
- The paper
- Huisman, M. T., Smit, J. W., & Schinkel, A. H. (2000). Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS. https://doi.org/10.1097/00002030-200002180-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.